The Oncology Institute, Inc. (NASDAQ:TOI) Director Mark L. Pacala Acquires 90,562 Shares

The Oncology Institute, Inc. (NASDAQ:TOI - Get Free Report) Director Mark L. Pacala bought 90,562 shares of the company's stock in a transaction that occurred on Wednesday, March 26th. The stock was purchased at an average cost of $1.04 per share, for a total transaction of $94,184.48. Following the transaction, the director now owns 224,971 shares in the company, valued at $233,969.84. The trade was a 67.38 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Oncology Institute Stock Up 10.5 %

TOI traded up $0.12 during trading hours on Tuesday, hitting $1.26. 1,194,217 shares of the company's stock were exchanged, compared to its average volume of 706,440. The stock has a market cap of $95.20 million, a price-to-earnings ratio of -1.62 and a beta of 0.41. The Oncology Institute, Inc. has a 1-year low of $0.13 and a 1-year high of $1.63. The stock's 50-day moving average is $0.88 and its two-hundred day moving average is $0.49. The company has a quick ratio of 2.27, a current ratio of 2.49 and a debt-to-equity ratio of 5.91.

Oncology Institute (NASDAQ:TOI - Get Free Report) last announced its quarterly earnings data on Monday, March 24th. The company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.08) by ($0.06). Oncology Institute had a negative net margin of 17.63% and a negative return on equity of 186.83%. The company had revenue of $100.27 million during the quarter, compared to the consensus estimate of $109.15 million.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the stock. Tiff Advisory Services LLC grew its stake in shares of Oncology Institute by 13.2% in the fourth quarter. Tiff Advisory Services LLC now owns 2,979,141 shares of the company's stock valued at $921,000 after buying an additional 346,256 shares in the last quarter. FreeGulliver LLC lifted its stake in Oncology Institute by 219.3% in the fourth quarter. FreeGulliver LLC now owns 600,747 shares of the company's stock valued at $186,000 after acquiring an additional 412,578 shares during the last quarter. Renaissance Technologies LLC grew its position in shares of Oncology Institute by 7.1% in the 4th quarter. Renaissance Technologies LLC now owns 182,000 shares of the company's stock valued at $56,000 after acquiring an additional 12,000 shares during the period. Virtu Financial LLC acquired a new position in shares of Oncology Institute during the 4th quarter worth about $41,000. Finally, Jane Street Group LLC raised its holdings in shares of Oncology Institute by 613.6% in the 4th quarter. Jane Street Group LLC now owns 127,659 shares of the company's stock valued at $39,000 after purchasing an additional 109,769 shares during the period. Institutional investors and hedge funds own 36.86% of the company's stock.

Oncology Institute Company Profile

The Oncology Institute, Inc, an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services.